QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed ...

Patients who are positive for homologous recombination deficiency (HDR) are also eligible and will receive poly ADP-ribose polymerase (PARP) inhibitor therapy as part of standard-of-care (SOC ...

The company’s gold-standard Genomic Instability Score (“GIS”) to determine Homologous Recombination Deficiency (“HRD”) will be reported for all samples analyzed with Illumina’s updated ...

it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option ...

A subgroup of participants who are positive for homologous recombination deficiency (HRD), which include BReast CAncer gene 1 (BRCA1) or BRCA2 mutations, will be given poly ADP-ribose polymerase ...

In four of six cases, the recombination resulting in the duplication occurred between homologous chromosomes (interchromosomal). In one duplication patient (1353), the duplication was derived from ...

Clinical relevance evaluation of a novel homologous recombination deficiency CE-IVD decentralized solution that identifies ovarian cancer patients that could potentially benefit from PARP-inhibitors.

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.